Hypereosinophilic Syndrome - 25 Studies Found
Available |
: This Record Contains Information About the Mepolizumab Compassionate Use Product Activities: 104317: An Open-Label Compassionate Use and Long-Term Access Study of Mepolizumab in HES 201956: A Long-term Access Programme for Subjects With Severe Asthma : Hypereosinophilic Syndrome : 2005-10-25 : Drug: Mepolizumab open label investigational product |
Completed |
: Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes :
: 2008-11-06 : Drug: Imatinib Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than c |
Completed |
: Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias :
|
Recruiting |
: Eosinophilia Diagnosis : Hypereosinophilic Syndrome : 2015-10-19 : Other: Scheduled exams and diagnosis Scheduled exams and diagnosis circuit as imposed by the algorithm |
Recruiting |
: Steroid Treatment for Hypereosinophilic Syndrome : Hypereosinophilia : 2012-02-01 : Drug: Corticosteroids |
Completed |
: 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) : Leukemia : 2007-06-05 :
|
Completed |
: Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome :
: 2005-12-15 : Drug: Mepolizumab 10mg/kg (max 750 ml) once a month for 3 months |
Completed |
: Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate :
|
Completed |
: Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) :
|
Completed |
: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes :
: Drug: imatinib mesylate Other Name: STI571 |